Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company dedicated to addressing critical unmet medical needs in neurodegenerative diseases with its proprietary nerve regeneration technology platform. The company focuses on developing groundbreaking therapeutics that aim to restore nerve function in conditions such as multiple sclerosis and spinal cord injuries. By advancing its clinical trials and expanding its intellectual property portfolio, NervGen is strategically positioned to capitalize on the growing demand for effective neurological treatments, presenting substantial growth potential and value creation opportunities for institutional investors.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$2.33
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | $-0.09 | $-0.37 | Miss -311.1% | — | $0 | $0 | — | 1D Pre+1.1% | On-Day0.0% | 1D Post-1.4% |
Q ended Mar 31, 2026 Reported May 18, 2026 | $-0.05 | $-0.06 | Miss -20.0% | — | $0 | $0 | — | 1D Pre-3.9% | On-Day+2.1% | 1D Post-2.2% |
Q ended Dec 31, 2025 Reported Mar 31, 2026 | $-0.07 | $-0.27 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Miss -285.7% |
| — |
| — |
| $0 |
| — |
| 1D Pre+1.9% |
| On-Day+1.1% |
| 1D Post+15.6% |
Q ended Sep 30, 2025 Reported Nov 25, 2025 | $-0.04 | $-0.04 | Met 0.0% | — | — | $0 | — | 1D Pre— | On-Day— | 1D Post-3.7% |